Arsenic in a cup: new oral formula could change leukemia treatment
NCT ID NCT06882031
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study looked at an oral arsenic solution (SDK001) in 12 people with acute promyelocytic leukemia (APL). Researchers wanted to see how the body processes the oral drug compared to the standard IV version, and whether food or calcium supplements affect absorption. The goal is to find a more convenient, pill-free option for controlling this blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Hong Kong-Clinical Trial Centre Phase 1 Centre
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.